$ONFO

Onfolio Holdings Inc. (NASDAQ:ONFO) Short Interest Update

Onfolio Holdings Inc. (NASDAQ:ONFO) saw short interest fall sharply in May, dropping to 186,032 shares as of May 15 from 901,491 on April 30, according to the report. Days to cover was 0.9 based on average daily volume. The stock traded at $0.66. On May 15, the company reported EPS of ($0.32) vs ($0.11) consensus and revenue of $1.87M vs $1.68M.

Original reporting
Published May 30, 2026, 11:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 30, 2026, 11:53 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Onfolio Holdings Inc. (NASDAQ:ONFO) Short Interest Update — source image
Decision brief

The 30-second read

$ONFONeutralMed
01

Why it matters

The combination of a large short-interest decline and a recent earnings miss suggests reduced bearish positioning but not a fundamental re-rating; traders may treat this as a positioning signal rather than a catalyst.

02

Market read

May short-interest fell sharply (79.4%), which can influence near-term supply/demand dynamics, but the earnings miss and sell ratings keep sentiment constrained.

03

What to watch

Very small market cap and thin liquidity (low volume vs average) can amplify price swings; days-to-cover <1 may also mean limited remaining short squeeze fuel.

Relevance 7/10Novelty 7/10Timing: after-hours/next-session positioning based on May short-interest data and post–May 15 earnings context

Background

Onfolio reported quarterly results on May 15 (EPS and margin negative) and the article now updates May 15 short-interest levels and days-to-cover.

Company-level read

Ticker impact

$ONFONeutralMedium confidence
Context

Article reports a sharp May short-interest decline (down 79.4% to 186,032 shares) alongside recent earnings miss and rating change.

Expected impact

Likely choppy/mean-reverting trading rather than a sustained trend; watch for follow-through after the May 15 earnings miss.

Evidence & confidence

The piece provides concrete short-interest and days-to-cover metrics, but no new operational catalyst beyond already-timed earnings and an analyst rating adjustment.

Market effects

Limited direct sector read-through; this is primarily single-name positioning/financing risk via short interest and leverage/liquidity ratios.

No clear regional spillover; micro-cap dynamics likely dominate.

Low—company-specific capital-market positioning rather than global macro or cross-border fundamentals.

Counterpoint

Short interest falling could reflect covering on weakness rather than improving fundamentals, so rallies may fade quickly.

Key entities

  • Onfolio Holdings, Inc.

    Subject of the short-interest update; also recently reported quarterly results and received a rating change.

  • Weiss Ratings

    Upgraded the stock from “sell (e+)” to “sell (d-)” in a research note.

Related articles

$ONFOMed

Why is Onfolio stock surging today?

Onfolio Holdings (ONFO) shares rose 21.6% in pre-open after the company reported Q2 2026 results before the market open. Analysts expected about $1.68M revenue and EPS of -$0.11. The move is attributed to the earnings release plus a 1-for-50 reverse split on Aug. 10, 2026, thin float, and high short interest (~46%).

$ONFOMed

Onfolio Announces Transformational Strategic Transaction with Paramount Helium, a Strategically Important US-Based Helium Resource

Onfolio Holdings (Nasdaq: ONFO, ONFOW) said it signed a binding LOI with Paramount Helium to combine and access a US helium resource. Paramount Helium would acquire the senior debt secured by Proton Green’s North America helium and CO2 assets. The St. Johns Unit in Arizona is estimated at over 20B cubic feet of helium and 3He core resources of 50+ kg valued at $10-$20M/kg, targeting semiconductor, space, and defense demand.

$ROIVMedAI 8/10

What Lisraya’s $35,000 Monthly Price Could Mean for Roivant (ROIV)

Roivant Sciences (ROIV) and Priovant Therapeutics launched Lisraya, a $35,000/month dermatomyositis treatment, post-FDA approval. The drug's high price and small patient population present challenges, but its immediate launch and long exclusivity may drive adoption. ROIV owns 71% of Priovant, making Lisraya's success crucial for its financial outlook.

$BEMed

Bloom Energy (BE) Joins S&P 500: Can Its AI Rally Continue?

Bloom Energy (BE) will join the S&P 500 on September 21, effective before market open. The company's stock surged over 150% in 2026, driven by demand for its power solutions in AI data centers. Bloom Energy reported 166% revenue growth in Q2 and raised its full-year revenue outlook to $3.9B-$4.2B. The company has partnerships with Oracle and Brookfield Asset Management, aiming to accelerate fuel cell deployment.